Research Summary

I am a medical oncologist with a specific interest in the genomics of cancer. My laboratory uses a variety of techniques to interrogate three basic themes in the biology and clinical behavior of these deadly cancers: (1) intra- patient tumor heterogeneity at the temporal and anatomic levels, (2) inter-patient heterogeneity between different patients, and (3) tumor-microenvironmental interactions. We use a combination of genetically engineered mouse models, cell lines, and clinically derived samples to interrogate multiple genomic outputs with a focus on genomic DNA and mRNA.

Research Funding

  • April 1, 2021 - March 31, 2026 - Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA256969
  • April 1, 2021 - March 31, 2026 - Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer, Principal Investigator. Sponsor: NIH, Sponsor Award ID: R01CA260860
  • April 1, 2019 - March 31, 2024 - The structural and functional basis of MET exon 14 activation and acquired drug resistance, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA230263
  • April 1, 2019 - March 31, 2024 - Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA239604

Education

UC Berkeley, BA, 1996 Genetics
UC Los Angeles, MD, 2002, Medicine

Honors & Awards

  • 1999
    Howard Hughes Medical Institute-NIH Research Scholar, Bethesda MD., Howard Hughes Medical Inst./NIH
  • 2001
    Alpha Omega Alpha, UCLA Chapter, AOA, UCLA
  • 2006
    Amgen Scholar, Amgen Foundation
  • 2007
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2012
    AACR PanCAN Career Development Award, American Association of Cancer Research
  • 2013
    Clinical Scholar Development Award , Doris Duke Charitable Foundation

Selected Publications

  1. Jiang H, Courau T, Borison J, Ritchie AJ, Mayer AT, Krummel MF, Collisson EA. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK blockade and CD40 Agonism. Gastroenterology. 2021 Oct 07.  View on PubMed
  2. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist. 2021 Sep 10.  View on PubMed
  3. Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, Cannon T, Shaw K, Petricoin EF, Klempner S, Lyons E, Wang-Gillam A, Pishvaian MJ, O'Reilly EM. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol. 2021; 5.  View on PubMed
  4. Hendley AM, Rao AA, Leonhardt L, Ashe S, Smith JA, Giacometti S, Peng XL, Jiang H, Berrios DI, Pawlak M, Li LY, Lee J, Collisson EA, Anderson MS, Fragiadakis GK, Yeh JJ, Ye CJ, Kim GE, Weaver VM, Hebrok M. Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree. Elife. 2021 05 19; 10.  View on PubMed
  5. Linossi EM, Estevam GO, Oshima M, Fraser JS, Collisson EA, Jura N. State of the structure address on MET receptor activation by HGF. Biochem Soc Trans. 2021 04 30; 49(2):645-661.  View on PubMed
  6. Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, Haan D, Yau C, Hinoue T, Liu Y, Shapira O, Kumar K, Mungall KL, Zhang H, June-Koo Lee J, Berger A, Gao GF, Zhitomirsky B, Liang WW, Zhou M, Moorthi S, Berger AH, Collisson EA, Zody MC, Ding L, Cherniack AD, Getz G, Elemento O, Benz CC, Stuart J, Zenklusen JC, Beroukhim R, Chang JC, Campbell JD, Hayes DN, Yang L, Laird PW, Weinstein JN, Kwiatkowski DJ, Tsao MS, Travis WD, Khurana E, Berman BP, Hoadley KA, Robine N, TCGA Research Network , Meyerson M, Govindan R, Imielinski M. Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 23; 34(8):108784.  View on PubMed
  7. Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, Haan D, Yau C, Hinoue T, Liu Y, Shapira O, Kumar K, Mungall KL, Zhang H, Lee JJ, Berger A, Gao GF, Zhitomirsky B, Liang WW, Zhou M, Moorthi S, Berger AH, Collisson EA, Zody MC, Ding L, Cherniack AD, Getz G, Elemento O, Benz CC, Stuart J, Zenklusen JC, Beroukhim R, Chang JC, Campbell JD, Hayes DN, Yang L, Laird PW, Weinstein JN, Kwiatkowski DJ, Tsao MS, Travis WD, Khurana E, Berman BP, Hoadley KA, Robine N, TCGA Research Network , Meyerson M, Govindan R, Imielinski M. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 02 02; 34(5):108707.  View on PubMed
  8. Amara D, Wisel SA, Braun HJ, Collisson EA, Friedlander T, Worner G, Roll GR, Hirose R, Stock PG. Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management Strategies. Transplant Direct. 2021 Jan; 7(1):e636.  View on PubMed
  9. Gonciarz RL, Collisson EA, Renslo AR. Ferrous Iron-Dependent Pharmacology. Trends Pharmacol Sci. 2021 01; 42(1):7-18.  View on PubMed
  10. Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P. Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients. J Natl Compr Canc Netw. 2020 11; 18(11):1446-1452.  View on PubMed
  11. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020 09 01; 130(9):4704-4709.  View on PubMed
  12. Cao W, Lee H, Wu W, Zaman A, McCorkle S, Yan M, Chen J, Xing Q, Sinnott-Armstrong N, Xu H, Sailani MR, Tang W, Cui Y, Liu J, Guan H, Lv P, Sun X, Sun L, Han P, Lou Y, Chang J, Wang J, Gao Y, Guo J, Schenk G, Shain AH, Biddle FG, Collisson E, Snyder M, Bivona TG. Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat Commun. 2020 07 22; 11(1):3675.  View on PubMed
  13. Collisson EA. Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer. Clin Cancer Res. 2020 09 15; 26(18):4715-4716.  View on PubMed
  14. Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020 09; 215(3):610-616.  View on PubMed
  15. Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clin Cancer Res. 2020 07 15; 26(14):3608-3615.  View on PubMed
  16. Glicksberg BS, Burns S, Currie R, Griffin A, Wang ZJ, Haussler D, Goldstein T, Collisson E. Blockchain-Authenticated Sharing of Genomic and Clinical Outcomes Data of Patients With Cancer: A Prospective Cohort Study. J Med Internet Res. 2020 03 20; 22(3):e16810.  View on PubMed
  17. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449.  View on PubMed
  18. Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019 07 11; 10(1):3055.  View on PubMed
  19. Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019 05; 569(7754):131-135.  View on PubMed
  20. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019 04; 16(4):207-220.  View on PubMed

Go to UCSF Profiles, powered by CTSI